Pharmafile Logo
Pharmafocus logo
Advanced Search

inlyta

Showing 14 posts of 14 posts found.

merck-keytruda-pembrolizumab-melanoma

NICE gives initial ‘no’ to NHS England for kidney cancer drug

February 18, 2020
Manufacturing and Production NHS England, NICE, clinical trials, inlyta, keytruda

The National Institute for Health and Care Excellence (NICE) has not recommended Keytruda (pembrolizumab) and Inlyta (axitinib) for the treatment …

News
credit_-_daniel_leal-olivas-afp

Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer

October 29, 2019
Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma

Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …

News
merck-keytruda

Keytruda/Inlyta combo scores FDA approval in advanced kidney cancer

April 23, 2019
Manufacturing and Production, Sales and Marketing FDA, MSD, Pfizer, Sutent, inlyta, keytruda, pharma

MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) has secured another approval from the FDA, this time as a first-line treatment in combination …

News
shutterstock_38078521

Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer

February 18, 2019
Research and Development, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma

New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that …

News
merckwindow_web

MSD’s Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma

February 18, 2019
Sales and Marketing Cancer, MSD, Merck Sutent, Pfizer, inlyta, keytruda, oncology, rcc, renal cell carcinoma

Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal …

News
merck-keytruda

Keytruda + Inlyta combo beats Pfizer’s chemotherapy Sutent in renal cell carcinoma

February 12, 2019
Manufacturing and Production, Research and Development Cancer, MSD, Pfizer, inlyta, keytruda, pharma, renal cell carcinoma

New data has been revealed on the efficacy of MSD’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib), showing it …

News
merckincweb

MSD’s Keytruda with Pfizer’s Inlyta beats Sutent in most common kidney cancer

October 19, 2018
Medical Communications, Research and Development Cancer, Kidney cancer, MSD, Pfizer, inlyta, keytruda, pharma

MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, …

News
pfizer_hq_dark

Pfizer shuts down kidney cancer drug trial due to “futility”

April 11, 2018
Research and Development Cancer, Kidney cancer, Pfizer, inlyta, pharma

Pfizer has revealed that it has shut down a trial of its vascular endothelial growth factor (VEGF) inhibitor Inlyta (axitinib) …

News
trials

Phase III trial initiated in Merck and Pfizer partnership for renal cell carcinoma drug

April 6, 2016
Research and Development Merck, Pfizer, avelumab, carcinoma, inlyta, javelin, partnership, phase III, renal

The first patient has been treated in the Phase III clinical trial, which sees Merck (ETR: MRK) and Pfizer (NYSE: …

News

Pfizer gets early approval for breast cancer drug

February 4, 2015
Sales and Marketing FDA, Pfizer, Xalkori (crizotinib), axitinib, bosulif, bosutinib, femara, ibrance, inlyta, letrozole, palbociclib

The FDA has shown Pfizer’s breast cancer drug Ibrance an early green light to treat patients who are at the …

News
Inlyta image

NICE backs Pfizer’s drug for advanced kidney cancer

December 16, 2014
Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo

UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …

News
Inlyta image

NICE U-turn on Pfizer drug Inlyta

March 5, 2014
Research and Development, Sales and Marketing Kidney cancer, NHS, NICE, Pfizer, axitinib, inlyta

NICE has recommended that Pfizer’s kidney cancer drug Inlyta should be used for some patients in England, following a similar …

News
Nexavar image

Torisel fails in head-to-head study with Nexavar

May 16, 2012
Research and Development, Sales and Marketing Bayer, Nexavar, Pfizer, Torisel, inlyta, rcc

Pfizer’s kidney cancer drug Torisel has failed to best Bayer’s Nexavar in a head-to-head trial.  The Phase III study was …

News
caprelsa image

Major new drugs for 2012

March 9, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Caprelsa, Eylea, Manjor new drugs, Xalkori, Zelboraf, avastin, inlyta

 Renal cell carcinoma Pfizer’s Inlyta (axitinib) has been approved as second line treatment for renal cell carcinoma. The drug is …

Feature

Latest content

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

October 2, 2023

Biogen’s biosimilar Tofidence approved by FDA

October 2, 2023

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023